Companies /Healthcare

Kymera Therapeutics Inc

NASDAQ: KYMR Biotechnology
$118.15
▼ $2.08 (−1.73%) today
Markets open · 10:05am ET

Q1 2025 Earnings

Reported May 9, 2025, 7:05am ET · SEC source
$-0.82
Beat +9.90%
EPS · est. $-0.91
$22.1M
Beat +105.88%
Revenue · est. $10.7M
+54.4%
Beating market
KYMR vs S&P since report
2 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−5%0+5%May 8May 16report 7:05am ETearnings+3.9%−4.5%
−5%0+5%May 8May 16earnings+3.9%−4.5%
KYMR −4.5%S&P 500 +3.9%
−5%0+5%May 8May 16report 7:05am ETearnings+5.1%−4.5%
−5%0+5%May 8May 16earnings+5.1%−4.5%
KYMR −4.5%NASDAQ +5.1%
−2.27%
Day of report
+6.98%
Next session
+0.60%
One week
+60.92%
30 days

S&P 500 over the same 30 days: +6.56%.

Did KYMR Beat Earnings? Q1 2025 Results

Kymera Therapeutics posted a quarter defined more by pipeline momentum than by its headline financials, as the clinical-stage biotech reported Q1 2025 revenue of $22.10 million and a loss of $0.82 per share, with collaboration income more than doubling year-over-year thanks to a $20.00 million milestone payment from Sanofi tied to the IRAK4 program. The net loss widened to $65.58 million from $48.56 million in Q1 2024, as R&D spending surged to $80.25 million, reflecting the company's accelerating bet on its STAT6 and newly unveiled IRF5 degrader programs. The headline development was the debut of KT-579, a first-in-class oral IRF5 degrader showing greater than 90% target degradation preclinically, with Phase 1 expected in early 2026. Meanwhile, the lead STAT6 asset KT-621 is tracking toward Phase 2b trials in atopic dermatitis and asthma by late 2025 and early 2026, respectively. A strategic decision to discontinue the TYK2 program KT-295 extended the company's cash runway into H1 2028, backed by $775.00 million on hand, though some analysts have flagged the shifting pipeline priorities as a source of near-term uncertainty.

Key Takeaways
  • Sanofi collaboration milestone payment of $20 million drove majority of Q1 2025 collaboration revenue increase
  • Increased R&D investment in STAT6 and TYK2 degrader programs, platform and discovery programs
  • Interest income of $8.9 million from cash and investment portfolio partially offset operating loss

“The Kymera team continues to advance our first-in-class pipeline on the path to revolutionizing the treatment of complex immuno-inflammatory diseases. We are making tremendous progress across our programs and approaching key near term inflection points. In June, we will be sharing the KT-621 healthy volunteer data for our STAT6 program, an important milestone in the development of this franchise. Additionally, we recently initiated, well ahead of schedule, patient dosing in the KT-621 BroADen Phase 1b study, with data in the fourth quarter of this year. This is another important inflection point as we rapidly progress KT-621 toward later-stage studies.”

Kymera Therapeutics CEO, on the earnings call

Forward Guidance & Outlook

Kymera expects to report complete KT-621 Phase 1 healthy volunteer SAD/MAD data in June 2025. KT-621 BroADen Phase 1b data in atopic dermatitis patients is expected in Q4 2025. Two parallel Phase 2b studies in AD and asthma are planned for Q4 2025 and Q1 2026 initiation, respectively. KT-579 (IRF5 degrader) is expected to enter Phase 1 clinical testing in early 2026. Sanofi-partnered KT-474 Phase 2b trials are expected to complete in H1 2026 (HS) and mid-2026 (AD). The company's decision to discontinue KT-295 (TYK2) extends its cash runway from mid-2027 into the first half of 2028, with $775 million in cash as of March 31, 2025.

KYMR YoY Financials

Revenue$22.1M
Operating Income$-74,426,000
Net Income$-65,581,000

KYMR Revenue by Segment

Sanofi Collaboration
Gilead Sciences Collaboration

Figures from SEC filings and company reports. Not investment advice.